Cumberland Pharmaceuticals (CPIX) Proxy Filing summary

Executive summary

• Annual meeting scheduled for April 22, 2025, with voting on director elections and auditor ratification.

• Shareholders can vote electronically, by mail, or in person; proxy materials are primarily distributed online to reduce costs and environmental impact.

• Board and management report on 2024 performance, including product development, regulatory milestones, and commercial partnerships.

Voting matters and shareholder proposals

• Shareholders will vote to elect three Class III directors for a three-year term and to ratify Carr, Riggs & Ingram, L.L.C. as the independent auditor for 2025.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• Shareholder proposals for the 2026 meeting must be submitted by November 13, 2025, to be included in the proxy statement.

Board of directors and corporate governance

• Board consists of seven directors in three staggered classes; five are independent.

• Committees include Audit, Compensation, and Governance & Nominating, each with written charters and full attendance in 2024.

• Lead Independent Director and combined Chairman/CEO structure; all directors attended the 2024 annual meeting.

• Governance Committee considers shareholder nominations and emphasizes diversity, ethics, and long-term commitment.